Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a **combination drug** composed of **ketotifen**, a mast cell stabilizer and H1-antihistamine, and a **vasoconstrictor** (component unspecified, as "vasoconstrictor" is a pharmacological action and could refer to any of several agents). Ketotifen works by inhibiting the release of histamine and other mediators from mast cells, providing anti-allergic and anti-inflammatory effects, and blocks H1 histamine receptors, reducing symptoms like itching, swelling, and wheezing[2]. Vasoconstrictors generally act by constricting blood vessels, reducing blood flow, and are commonly used in ophthalmic, nasal, or local anesthetic products. The combination would provide both mast cell stabilization and reduced vascular permeability/bleeding; however, the precise mechanism and safety profile will depend on the specific vasoconstrictor used. In vascular physiology studies, ketotifen altered the vasoconstrictor response in arteries, acting mainly by reducing neuronal nitric oxide release and histamine-mediated responses[1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ketotifen + vasoconstrictor.